keyword
MENU ▼
Read by QxMD icon Read
search

Tudorza

keyword
https://www.readbyqxmd.com/read/24812502/clinical-use-of-aclidinium-in-patients-with-copd
#1
REVIEW
Debra J Reid, Alexa A Carlson
Chronic obstructive pulmonary disease (COPD) is the sixth-leading cause of death in the US. The Global initiative for Chronic Obstructive Lung Disease (GOLD) guidelines provide evidence-based recommendations for the clinical management of chronic COPD. Long-acting inhaled bronchodilators continue to be the mainstay of current management. Aclidinium bromide (Tudorza™ Pressair™) joins tiotropium as a long-acting inhaled antimuscarinic bronchodilator approved by the US Food and Drug Administration for the maintenance treatment of COPD...
2014: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/24534593/aclidinium-bromide-for-the-treatment-of-chronic-obstructive-pulmonary-disease
#2
REVIEW
Lowell E Stone, Jessica W Skelley, Jeffrey A Kyle, Lindsey K Elmore
PURPOSE: The safety and efficacy of the second U.S.-approved long-acting inhaled anticholinergic for controlling bronchospasm in patients with chronic obstructive pulmonary disease (COPD) are reviewed. SUMMARY: Aclidinium bromide (Tudorza, Forest Pharmaceuticals) is indicated for long-term maintenance therapy for COPD-associated bronchospasm. It is marketed as a 60-dose metered-dose inhaler to be used twice daily. In Phase II and III clinical trials involving a total of more than 3000 patients, daily use of aclidinium bromide was found to significantly improve selected key indicators of lung function (trough values for forced expiratory volume at one second [FEV1] and other FEV1 outcome measures) compared with placebo use...
March 1, 2014: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/24049425/aclidinium-bromide-inhalation-powder-tudorza-a-long-acting-anticholinergic-for-the-management-of-chronic-obstructive-pulmonary-disease
#3
Michele Pisano, Nissa Mazzola
Aclidinium bromide inhalation powder (Tudorza) for COPD.
July 2013: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/23223246/aclidium-bromide-tudorza-pressair-for-copd
#4
REVIEW
(no author information available yet)
No abstract text is available yet for this article.
December 10, 2012: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/23066343/pharmaceutical-approval-update
#5
Marvin M Goldenberg
Lorcaserin (Belviq), an appetite suppressant; pertuzumab (Perjeta) for HER-2- positive metastatic breast cancer; MenHibrix vaccine for meningococcal infections and influenza; icosapent ethyl (Vascepa) for reducing triglycerides; and aclidinium inhalation (Tudorza) powder for bronchospasm in COPD.
September 2012: P & T: a Peer-reviewed Journal for Formulary Management
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"